BR112022025634A2 - Composto ou sal farmaceuticamente aceitável do mesmo, método de preparação do composto e composições - Google Patents

Composto ou sal farmaceuticamente aceitável do mesmo, método de preparação do composto e composições

Info

Publication number
BR112022025634A2
BR112022025634A2 BR112022025634A BR112022025634A BR112022025634A2 BR 112022025634 A2 BR112022025634 A2 BR 112022025634A2 BR 112022025634 A BR112022025634 A BR 112022025634A BR 112022025634 A BR112022025634 A BR 112022025634A BR 112022025634 A2 BR112022025634 A2 BR 112022025634A2
Authority
BR
Brazil
Prior art keywords
compound
compositions
pharmaceutically acceptable
acceptable salt
preparation
Prior art date
Application number
BR112022025634A
Other languages
English (en)
Inventor
Nim Pae Ae
Kyung Kim Yun
Min Lim Sang
Lim Sungsu
Lee Haeun
Seung Son Woo
Yeon Lee Hye
Original Assignee
Korea Inst Sci & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Inst Sci & Tech filed Critical Korea Inst Sci & Tech
Publication of BR112022025634A2 publication Critical patent/BR112022025634A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO OU SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO, MÉTODO DE PREPARAÇÃO DO COMPOSTO E COMPOSIÇÕES. A presente invenção refere-se a um composto de dicianida oxopiridazinil-fenil-carbonohidrazonoil inovador e uso do mesmo.
BR112022025634A 2020-06-19 2021-06-18 Composto ou sal farmaceuticamente aceitável do mesmo, método de preparação do composto e composições BR112022025634A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200075040A KR102356644B1 (ko) 2020-06-19 2020-06-19 신규한 옥소피리다지닐-페닐-카르보노하이드라조노일 디시아나이드 화합물 및 이의 용도
PCT/KR2021/007692 WO2021256900A1 (ko) 2020-06-19 2021-06-18 신규한 옥소피리다지닐-페닐-카르보노하이드라조노일 디시아나이드 화합물 및 이의 용도

Publications (1)

Publication Number Publication Date
BR112022025634A2 true BR112022025634A2 (pt) 2023-01-17

Family

ID=79178262

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025634A BR112022025634A2 (pt) 2020-06-19 2021-06-18 Composto ou sal farmaceuticamente aceitável do mesmo, método de preparação do composto e composições

Country Status (9)

Country Link
US (1) US20230278963A1 (pt)
EP (1) EP4169909A1 (pt)
JP (1) JP2023530314A (pt)
KR (1) KR102356644B1 (pt)
CN (1) CN115867279A (pt)
AR (1) AR122675A1 (pt)
BR (1) BR112022025634A2 (pt)
TW (1) TWI783535B (pt)
WO (1) WO2021256900A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519878A (ja) * 2001-11-30 2005-07-07 キネテク ファーマシューティカルズ，インコーポレーテッド ヒドラゾノピラゾール誘導体および治療剤としてのその使用
AU2010272364B2 (en) * 2009-07-14 2014-04-10 Cipla Limited Process for preparing levosimendan and intermediates for use in the process
CN104418810A (zh) 2013-09-04 2015-03-18 北京博时安泰科技发展有限公司 一种左西孟旦的合成新路线
CN104987310A (zh) 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
EP3424908A1 (en) * 2017-07-07 2019-01-09 Melody Healthcare Pvt. Ltd. Process for preparation of levosimendan
US9962384B1 (en) * 2017-09-07 2018-05-08 Korea Institute Of Science And Technology Levosimendan compound for preventing or treating tau-related diseases
WO2020041180A1 (en) 2018-08-21 2020-02-27 Tenax Therapeutics, Inc. Pharmaceutical compositions for subcutaneous administration of levosimendan
KR102128509B1 (ko) * 2018-12-19 2020-07-01 한국과학기술연구원 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도

Also Published As

Publication number Publication date
EP4169909A1 (en) 2023-04-26
TWI783535B (zh) 2022-11-11
KR20210157134A (ko) 2021-12-28
WO2021256900A1 (ko) 2021-12-23
TW202200550A (zh) 2022-01-01
US20230278963A1 (en) 2023-09-07
CN115867279A (zh) 2023-03-28
KR102356644B1 (ko) 2022-01-28
AR122675A1 (es) 2022-09-28
JP2023530314A (ja) 2023-07-14

Similar Documents

Publication Publication Date Title
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
GEP20237506B (en) Pcsk9 antagonist compounds
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
BR112012024796A2 (pt) inibidores de integrase macrocíclicos
MD3464249T2 (ro) Derivați carbonucleozidici substituiţi utili în calitate de agenți anticanceroşi
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
BR112021019748A2 (pt) Degradadores de stat e usos dos mesmos
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BR112022000598A2 (pt) Composto de ureia para antagonização de receptor de lpa1
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112018075639A2 (pt) conjugados de anticorpo fármaco anti-egfr
BR112021011325A2 (pt) Derivados de rapamicina
WO2019118411A3 (en) Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
BR112015026840A2 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia
BR112018074985A2 (pt) composições antibacterianas
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
BR112012009311A2 (pt) composto, composição farmacêutica, e, uso do composto
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
BR112021020027A2 (pt) Compostos, composições e métodos
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
EA202192388A1 (ru) Составы против микробиоты для чрескожного применения